Skip to content

Study · Randomized controlled trial · n = 149 · 2000

3 results

Randomized trial of adjuvant tamoxifen and/or goserelin in premenopausal breast cancer--self-rated physiological effects and symptoms.

Nystedt M, Berglund G, Bolund C, Brandberg Y, Fornander T, Rutqvist LE

Acta oncologica (Stockholm, Sweden)1 Jan 2000Cited by 29 (Europe PMC)

PMID11207003 (opens in a new tab)DOI10.1080/02841860050215945 (opens in a new tab)PepBankPUB-11207003
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In premenopausal breast cancer patients, anxiety symptoms did not differ significantly among groups, including goserelin.

    In plain wordsIn premenopausal breast cancer patients, anxiety symptoms did not differ significantly among groups, including goserelin.

    Peptide
    Goserelin
    Outcome
    No significant changeAnxiety symptoms
    Study

    n = 149

    Comparator
    other randomized groups
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No significant group differences were found for anxiety and depressive symptoms.
    2 context sentences
    Summary · context
    After primary surgery, 149 premenopausal breast cancer patients, with node-negative disease, were randomized to one of four treatment groups: goserelin, tamoxifen, goserelin plus tamoxifen or to a systematically untreated control group.
    Summary · context
    Assessments were made before randomization, at 3-4 months and at 12 months.
  2. 02HumanRandomized controlled trialSafety outcome

    In premenopausal breast cancer patients, depressive symptoms did not differ significantly among groups, including goserelin.

    In plain wordsIn premenopausal breast cancer patients, depressive symptoms did not differ significantly among groups, including goserelin.

    Peptide
    Goserelin
    Outcome
    No significant changeDepressive symptoms
    Study

    n = 149

    Comparator
    other randomized groups
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No significant group differences were found for anxiety and depressive symptoms.
    2 context sentences
    Summary · context
    After primary surgery, 149 premenopausal breast cancer patients, with node-negative disease, were randomized to one of four treatment groups: goserelin, tamoxifen, goserelin plus tamoxifen or to a systematically untreated control group.
    Summary · context
    Assessments were made before randomization, at 3-4 months and at 12 months.
  3. 03HumanRandomized controlled trialSafety outcome

    In premenopausal breast cancer patients, goserelin produced earlier and more intense menopausal symptoms than tamoxifen.

    In plain wordsIn premenopausal breast cancer patients, goserelin produced earlier and more intense menopausal symptoms than tamoxifen.

    Peptide
    Goserelin
    Outcome
    IncreaseMenopausal symptoms
    Study

    n: not reported in source

    Comparator
    tamoxifen
    Outcome group
    Adverse events · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Treatment with goserelin resulted in early and more intense menopausal symptoms, while the effects of tamoxifen were slower and milder.
    2 context sentences
    Summary · context
    After primary surgery, 149 premenopausal breast cancer patients, with node-negative disease, were randomized to one of four treatment groups: goserelin, tamoxifen, goserelin plus tamoxifen or to a systematically untreated control group.
    Summary · context
    Assessments were made before randomization, at 3-4 months and at 12 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.